Download the eBook here >>

We asked several industry experts at the World Vaccine Congress USA 2013 the following three questions:

• What role do you see the developing world taking in relation to vaccine development?
• Does the industry need to rethink its approach to regulatory approval in light of low approval rates?
• What technological advances could revolutionise the vaccine industry in the next 12 months?

This eBook outlines their responses. Read their answers and see what you think. Their responses are also available as a video – watch the video here. I look forward to hearing your thoughts. You can join our discussion on LinkedIn or leave a comment below, I’d love to hear what you think. Want more from Vaccine Nation? Sign up to our newsletter for here.

The 14th annual World Vaccine Congress Europe 2013 is where innovation and expertise are showcased, solutions are found and  the region’s biggest opportunities are discovered.

“As a privileged Shale World reader, we are pleased to offer a special discount on purchase of GlobalData reports upto 31 Dec’12.

Use Your online 20% discount code for GlobalData reports is ‘GDPC667’

Samuel Bogoch

Download the whitepaper here.

The whitepaper argues that, “the possibility of preventing the development of influenza virus outbreaks and pandemics is being considered for the first time because quantitative changes in the genome have been shown to predict strain-specific outbreaks and the particular geographic locations where outbreaks will occur.”

Dr. Bogoch’s discovery of Replikins, their concentration, conservation, and trans-strain sharing in the influenza genomes, and their relationship to rapid replication and advance warning of virus outbreaks, permitted the prediction in 2008 of the last H1N1 Pandemic of 2009, six other correct predictions of influenza outbreaks, and of the geographic location of these outbreaks, and a prediction one year in advance of the current Foot and Mouth Disease outbreaks in Asia, the middle East and Europe.

Download the whitepaper now for more information on pandemic prediction and H5N1 influenza vaccines.

Current data on SARS and H5N1 will be presented at Influenza Congress USA this November.

The complete solid-phase synthesis of the Replikins TransFlu®Vaccine which, without any biological constituents, has blocked both replication and excretion of H5N1 in chickens is also of interest. Early warning, for the first time, provides the time needed to make optimal public health preparations and to produce and thoroughly test synthetic vaccines based on the specific Replikins genomic components identified in advance which are proceeding toward an outbreak, as well as the location of such outbreak. Thus it is possible now, for the first time, to begin testing pandemic prevention with synthetic vaccines.

Dr. Bogoch will be presenting on this topic – ‘The present and future: Solid phase synthetic vaccines’ – at Influenza Congress USA. Register now to hear him share his expertise!

Eluemuno Blyden

Download the whitepaper here.

Originally published by IEEE, the whitepaper states that “recombinant vector technologies for embryonated hen eggs are an emerging platform for global health applications including production of vaccines and biologics.” It goes on to suggest that “industrializing these new platforms requires investment in translational research at molecular, machine, and systems levels,” but that once done, this type of system could offering an “attractive solution to global health challenges including influenza pandemic preparedness.”

The whitepaper looks at:

• How eggs are used to make vaccines today
• Learning from the global influenza vaccine enterprise
  • Coordinated global surveillance and manufacturing
  • Vertically integrating new egg-based technologies
  • Improving the molecular processes
  • Improvements in manufacturing processes – automation
  • Poultry Pharming – next generation egg-based enterprises
  • Sustaining readiness – more plural models are needed

To learn more about this, check out the whitepaper now!

Eluemuno will speak at the upcoming Influenza Congress USA on the topic ‘Manufacturing technologies for recombinant products in embryonated eggs.’ Register now to hear him speak, or download the brochure for more information.

Download the whitepaper here.

In the paper, the authors suggest that “protective immunity against influenza virus infection is mediated by neutralizing antibodies, but the precise role of T cells in human influenza immunity is uncertain.”

Because of this, they undertook an influenza infection study, where they mapped T cell responses to influenza before and during infection. They found that “preexisting CD4+, but not CD8+, T cells responding to influenza internal proteins were associated with lower virus shedding and less severe illness,” and “these CD4+ cells also responded to pandemic H1N1 […] peptides and showed evidence of cytotoxic activity.”

The authors go on to suggest that “these cells are an important statistical correlate of homotypic and heterotypic response and may limit severity of influenza infection by new strains in the absence of specific antibody responses. [These] results provide information that may aid the design of future vaccines against emerging influenza strains.”

The whitepaper discusses in more detail:

• Human influenza infection model
• Antibody and T cell responses
• Preexisting T cell responses, viral shedding and symptom scores
• Preexisting T cells against nucleoprotein and matrix protein
• Heterosubtypic memory CD4+ T cell responses

For more information on this, make sure you download the whitepaper now.

Rob Lambkin-Williams, Chief Scientific Officer of Retroscreen Virology, will be speaking at the upcoming Influenza Congress USA conference on the topic, ‘Conducting human viral challenge studies to address patient recruitment difficulties.’ Retroscreen Virology is a sponsor of this event.

Dr. Annie DeGroot

Annie kindly provided these whitepapers, entitled ‘Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4+ T cells against the swine-origin H1N1 influenza virus,’ and ‘Time for T? Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T cell epitopes in the next generation of influenza vaccines.’

Download the first whitepaper on in vitro and in silico techniques here.

Download the second whitepaper on the role of T cell epitopes here.

In the first paper, the authors look at the 2009 H1N1 influenza outbreak, and the resulting efforts to produce large quantities of vaccine doses to protect against this virus strain. “Of particular concern was the apparent lack of pre-existing antibody capable of eliciting crossprotective immunity against this novel virus, which fueled fears this strain would trigger a particularly far-reaching and lethal pandemic.” However, as the pandemic was far less severe than expected, the authors suggest that “cellular immunity to cross-conserved T cell epitopes might have played a significant role in protecting against the pandemic H1N1 in the absence of cross-reactive humoral immunity.” They propose that “pre-existing CD4+ T cells can elicit crossreactive effector responses against the pandemic H1N1 virus.”

Download the whitepaper now for more information on this.

In the second paper, the authors look at the role of T cell epitopes in next-gen flu vaccines. They suggest that, “there might be cross-protective immunity due to previously circulating influenza virus and the novel H1N1… Was it possible that – in the absence of cross-protective antibodies – T cells were contributing enough of a protective immune response to protect some individuals against novel H1N1?”

To find out, download the whitepaper now.

Influenza Congress USA is taking place this November in Washington, D.C. Download the brochure now for more information.

Check out these two whitepapers, kindly provided by Joost, discussing the MVA based vaccine platform against the H5N1 virus, and some of the work taking place at Erasmus Medical Center with recombinants and the H5N1 virus.

The first whitepaper, entitled ‘Recombinant Modified Vaccinia Virus Ankara Expressing the Hemagglutinin Gene Confers Protection against Homologous and Heterologous H5N1 Influenza Virus Infections in Macaques,’ looks at the Erasmus MVA H5N1 vaccine study, and how this could be a promising vaccine candidate for the induction of protective immunity against highly pathogenic H5N1 avian influenza viruses in humans.

Download the whitepaper on recombinant modified vaccinia virus Ankara here.

The second whitepaper, entitled ‘MVA-Based H5N1 Vaccine Affords Cross-Clade Protection in Mice against Influenza A/H5N1 Viruses at Low Doses and after Single Immunization,’ looks at a study on mice that suggests that MVA-based vaccines allows significant dose-sparing and affords cross-clade protection.

Download the whitepaper on the MVA-based H5N1 vaccine here.

Erasmus has been at the forefront of influenza vaccine research and development. You cannot miss this discussion at Influenza Congress USA! Register now to confirm your seat.

The Managing Director of Anovasia, John Dangerfield shared a unique platform technology called Molecular Painting (MP) at the World Vaccine Congress Asia. He defined MP as the surface modification of biomembranes and MP reagents are based on natural products.  The main industrial application areas are:

• Basic and Applied Research
• Diagnostics, Biomarkers
• Vaccine Development
• Targeting and Delivery of Genes, Proteins and/or Drugs
• Cell and Gene Therapy

MP works in the 3 simple steps and he stated key advantages to using this technology in this presentation. Examples of applications were also given during his presentation. For more information on the steps involved and examples, download his presentation here.

If you would like to present your technology to key Asian vaccine industry stakeholders, join us at World Vaccine Congress Asia. Visit our website for more details: www.terrapinn.com/vaccineasia

The 6th annual World Vaccine Congress Asia in June was yet again a record-breaking success – hosting over 300 attendees and featuring over 80 world class speakers from the vaccine industry.

The conference has once again, demonstrated that IT IS THE vaccine industry platform in Asia for serious business networking and learning.

Click here to download a copy of the post-event report and have a look at what happened at the World Vaccine Congress Asia.

Save the dates now and join us in 2013 – The 7^th annual World Vaccine Asia Congress will take place from 3rd – 6th June 2013 in Singapore.  Join us and be a part of the World Vaccine Congress as it brings together all the major vaccine stakeholders, through pharmas, biotechs, NGOs, research institutes, regulators and CDCs to discuss latest industry trends, business strategies and scientific developments in the global and Asian vaccine markets.

Visit the website for more information!

Key quotes and findings from the State of the World’s Vaccines and Immunization Report

“ Immunization is one of the most powerful and cost-effective of all health interventions.  It prevents debilitating illness and disability, and saves millions of lives every year. It  is also key to achieving the Millennium Development Goals (MDGs) – commitments made by world leaders in 2000 to reduce poverty and improve human development.  The contribution of immunization is especially critical to achieving the goal to reduce  deaths among children under five years old (MDG 4).”

Overview:

“WHO has estimated that if all the vaccines now available against  childhood diseases were widely adopted, and if countries could raise vaccine  coverage to a global average of 90%, by 2015 an additional two million deaths  a year could be prevented among children under five years old.”

Vaccine development:

“Since the year  2000, the global vaccine market has almost tripled – reaching over US$ 17 billion  in global revenue by mid-2008, and making the vaccine industry one of the fastest  growing sectors of industry. Most of this expansion comes from sales in industrialized countries of newer, more costly vaccines, which account for more than half of the total value of vaccine sales worldwide.”

Barriers:

“A major barrier is the underlying weakness of the health system  in many developing countries. Another is the difficulty in delivering vaccines through  an infrastructure and logistical support system that is often overloaded. Yet another  is a lack of understanding about the importance of vaccines – especially among  the poorest populations – and a failure to actively demand access to immunization services.”

“One change, however, that could seriously imperil efforts to battle inequity,  preventable disease, death, and poverty, is the collapse of global financial markets  in the last months of 2008, and the economic slowdown that has since swept over the world.”

Costs:

“By 2010, the average cost of immunizing a child is projected to rise to about  US$ 18.00 per live birth. Beyond 2010, scaling up vaccine coverage with new  vaccines – such as pneumococcal and rotavirus vaccines – to meet the MDGs and  the GIVS goals is likely to raise the cost above US$ 30.00 per live birth.”

Global Immunization Vision and Strategy goals:

Read the full report here

Have you read the report? Let us know what you think by commenting below.

For more on updates and information regarding the vaccines industry, join the conversation on Twitter @vaccinenation